Biotech Values

[oldberkeley]

The prospective buyers of the offering may have initially questioned whether MNTA would aggressively defend its IP, and hence the closeness in time of the financing and MNTA’s lawsuit against Teva might not be coincidence.

Just what I was driving at.

You know as well as I do the extent that backroom negotiating drives all big business. I'm not happy but I also know that this wasn't done on the spur of the moment and we're seeing a "long game" strategy play out. These are not stupid or inexperienced people.

I think that the price of the offering is crucial; if it's good, the situation is good. If it's a fire sale, for whatever reason, we've got a fire sale situation on our hands.